EA201190080A1 - Стабильные формы гранулоцитарных колоний рекомбинантного человеческого альбумина, стимулирующие фактор гибридного белка - Google Patents

Стабильные формы гранулоцитарных колоний рекомбинантного человеческого альбумина, стимулирующие фактор гибридного белка

Info

Publication number
EA201190080A1
EA201190080A1 EA201190080A EA201190080A EA201190080A1 EA 201190080 A1 EA201190080 A1 EA 201190080A1 EA 201190080 A EA201190080 A EA 201190080A EA 201190080 A EA201190080 A EA 201190080A EA 201190080 A1 EA201190080 A1 EA 201190080A1
Authority
EA
Eurasian Patent Office
Prior art keywords
stimulating factor
granulocitarian
colonies
recombinant human
human albumin
Prior art date
Application number
EA201190080A
Other languages
English (en)
Other versions
EA023344B1 (ru
Inventor
Джейсон Бенджамин Бок
Адам Карр Белл
Джеффри Херпст
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201190080A1 publication Critical patent/EA201190080A1/ru
Publication of EA023344B1 publication Critical patent/EA023344B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

Предложены композиции и способы лечения, предотвращения и облегчения патологических состояний и заболеваний, характеризующихся пониженным числом лейкоцитов крови. Способы и композиции, описанные в настоящей заявке, включают гибридный полипептид, образованный из белка сывороточного альбумина человека ("HSA") и гранулоцитарного колониестимулирующего фактора человека ("G-CSF").
EA201190080A 2009-01-16 2010-01-15 Способ лечения или предотвращения нейтропении или лейкопении или снижения частоты возникновения инфекции, проявляющейся фебрильной нейтропенией EA023344B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14543609P 2009-01-16 2009-01-16
US14544009P 2009-01-16 2009-01-16
PCT/US2010/021241 WO2010083439A2 (en) 2009-01-16 2010-01-15 Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia

Publications (2)

Publication Number Publication Date
EA201190080A1 true EA201190080A1 (ru) 2014-03-31
EA023344B1 EA023344B1 (ru) 2016-05-31

Family

ID=42260335

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201190079A EA201190079A1 (ru) 2009-01-16 2010-01-15 Новые стабильные составы рекомбинантного альбумина человека-гранулоцитарного колониестимулирующего фактора человека
EA201190080A EA023344B1 (ru) 2009-01-16 2010-01-15 Способ лечения или предотвращения нейтропении или лейкопении или снижения частоты возникновения инфекции, проявляющейся фебрильной нейтропенией

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201190079A EA201190079A1 (ru) 2009-01-16 2010-01-15 Новые стабильные составы рекомбинантного альбумина человека-гранулоцитарного колониестимулирующего фактора человека

Country Status (16)

Country Link
US (4) US8323634B2 (ru)
EP (2) EP2387420A2 (ru)
JP (2) JP5753095B2 (ru)
KR (2) KR20110132326A (ru)
CN (2) CN102378635A (ru)
AU (2) AU2010204552B2 (ru)
BR (2) BRPI1005159A2 (ru)
CA (2) CA2749802C (ru)
EA (2) EA201190079A1 (ru)
IL (2) IL214051A0 (ru)
MX (2) MX2011007583A (ru)
NZ (2) NZ594056A (ru)
SG (3) SG172941A1 (ru)
UA (2) UA103221C2 (ru)
WO (2) WO2010083434A2 (ru)
ZA (1) ZA201105171B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5753095B2 (ja) * 2009-01-16 2015-07-22 テバ ファーマシューティカル インダストリーズ リミテッド 組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
DK2575935T4 (da) * 2010-06-07 2023-11-27 Amgen Inc Anordning til indgivelse af lægemiddel
CN102628869B (zh) * 2012-04-19 2014-04-02 上海蓝怡科技有限公司 提高甲胎蛋白抗体冻干稳定性的制剂
EP2945703A4 (en) * 2013-01-15 2016-08-31 Teva Pharma ALBU-BCHE FORMULATIONS, PREPARATION THEREOF AND USES THEREOF
WO2014147489A2 (en) 2013-03-15 2014-09-25 Teva Pharmaceutical Industries Ltd. Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia in pediatric patients
MA40904A (fr) * 2014-11-03 2017-09-12 Hygeia Tech Inc Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
BE1023343B1 (nl) * 2015-05-20 2017-02-09 Mycartis Nv Opslagbuffer
ES2852002T3 (es) * 2015-07-30 2021-09-10 Endor Tech S L Factor estimulante de colonias para su uso en el tratamiento del cáncer de páncreas o de colon
CA3013467A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
CN106222221A (zh) * 2016-08-05 2016-12-14 山东科兴生物制品有限公司 制备重组人粒细胞刺激因子原液的纯化方法
US11278665B2 (en) 2016-11-22 2022-03-22 Eitan Medical Ltd. Method for delivering a therapeutic substance
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
US20210088505A1 (en) * 2017-04-07 2021-03-25 La Jolla Institute For Allergy And Immunology Unipotent Neutrophil Progenitor Cells, Methods of Preparation, and Uses Thereof
CN109420159A (zh) * 2017-08-23 2019-03-05 江苏泰康生物医药有限公司 一种重组蛋白药物的新型稳定制剂
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia
KR20200116477A (ko) * 2018-02-01 2020-10-12 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 및 g-csf 제제의 투여를 통해 화학요법-유도된 호중구감소증을 감소시키기 위한 조성물 및 방법
US11583633B2 (en) 2018-04-03 2023-02-21 Amgen Inc. Systems and methods for delayed drug delivery
US11357909B2 (en) 2018-10-05 2022-06-14 Eitan Medical Ltd. Triggering sequence
CN111383745A (zh) * 2018-12-29 2020-07-07 医渡云（北京）技术有限公司 计算机数据处理方法、装置、存储介质及设备
US11267858B2 (en) 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
CN112316120A (zh) * 2019-08-05 2021-02-05 天津派格生物技术有限公司 使用低动员型g-csf有效且安全治疗粒细胞减少症的方法
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
CN111751552B (zh) * 2020-06-18 2022-09-16 广州市伊川生物科技有限公司 一种缺血修饰白蛋白测定试剂盒及其使用方法
US11723955B1 (en) * 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU613030B2 (en) 1987-04-09 1991-07-25 Novozymes Delta Limited Yeast vector
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US7321023B2 (en) * 1997-11-07 2008-01-22 Incyte Corporation SP16 protein
EP1060746A4 (en) * 1998-03-06 2002-06-19 Chugai Pharmaceutical Co Ltd PROTEIN-FREE PREPARATIONS
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
WO2001079442A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
JP2004532277A (ja) * 2001-06-08 2004-10-21 パウダージェクト ワクチンズ，インコーポレーテッド 噴霧凍結乾燥組成物
ES2500918T3 (es) * 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004082640A2 (en) * 2003-03-19 2004-09-30 New Century Pharmaceuticals, Inc. Human serum albumin conjugates with therapeutic compounds
US6972332B1 (en) * 2004-05-20 2005-12-06 Acura Pharmaceuticals, Inc. Process for the production of opiates
WO2007021494A2 (en) * 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
MX2007004529A (es) * 2006-04-13 2008-12-01 Wix Filtration Corp Llc Elemento de filtro.
JP2008146587A (ja) * 2006-12-13 2008-06-26 Sony Corp 表示装置、表示プログラム、表示方法、画像提供装置、画像提供プログラム、画像提供方法及び記録媒体
JP5753095B2 (ja) 2009-01-16 2015-07-22 テバ ファーマシューティカル インダストリーズ リミテッド 組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤

Also Published As

Publication number Publication date
US20100297062A1 (en) 2010-11-25
SG172941A1 (en) 2011-08-29
AU2010204552B2 (en) 2014-05-01
CA2749802C (en) 2016-08-23
EA201190079A1 (ru) 2013-02-28
US20150202268A1 (en) 2015-07-23
MX2011007582A (es) 2011-12-14
IL214052A0 (en) 2011-08-31
CA2749802A1 (en) 2010-07-22
KR20110132327A (ko) 2011-12-07
US8993519B2 (en) 2015-03-31
CN102395379B (zh) 2015-07-22
JP2012515221A (ja) 2012-07-05
EP2387420A2 (en) 2011-11-23
AU2010204547A1 (en) 2011-07-28
NZ594056A (en) 2013-03-28
BRPI1005159A2 (pt) 2018-04-03
CN102395379A (zh) 2012-03-28
AU2010204552A1 (en) 2011-08-04
BRPI1004940A2 (pt) 2018-06-19
EA023344B1 (ru) 2016-05-31
WO2010083434A3 (en) 2010-09-10
CN102378635A (zh) 2012-03-14
WO2010083439A2 (en) 2010-07-22
NZ594055A (en) 2013-03-28
SG172940A1 (en) 2011-08-29
EP2387419A2 (en) 2011-11-23
US20130129669A1 (en) 2013-05-23
UA103221C2 (ru) 2013-09-25
IL214051A0 (en) 2011-08-31
JP2012515222A (ja) 2012-07-05
AU2010204547B2 (en) 2014-01-23
UA105201C2 (ru) 2014-04-25
CA2749786A1 (en) 2010-07-22
JP5753095B2 (ja) 2015-07-22
ZA201105171B (en) 2015-12-23
US8323634B2 (en) 2012-12-04
WO2010083434A2 (en) 2010-07-22
US20100227818A1 (en) 2010-09-09
WO2010083439A3 (en) 2010-09-10
KR20110132326A (ko) 2011-12-07
SG196821A1 (en) 2014-02-13
MX2011007583A (es) 2011-12-14

Similar Documents

Publication Publication Date Title
EA201190080A1 (ru) Стабильные формы гранулоцитарных колоний рекомбинантного человеческого альбумина, стимулирующие фактор гибридного белка
EA201200515A1 (ru) Полипептиды и их применение
EP2987807A3 (en) Antibodies recognising phospho-tau
EA201390739A1 (ru) Способ лечения fgf21-ассоциированных расстройств
MX2007001638A (es) Proteinas de fusion del dominio de unión.
EA200971056A1 (ru) ПРОДУЦИРОВАНИЕ РЕКОМБИНАНТНЫХ БЕЛКОВ В КЛЕТКАХ ПТИЦ Еbx®
TN2014000109A1 (en) Fusion proteins for treating metabolic disorders
PH12015502017A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune disease
EA201170993A1 (ru) Удлиненные рекомбинантные полипептиды и содержащие их композиции
MX2012007318A (es) Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia.
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
EA201070553A1 (ru) Антитела к гепцидину и варианты их применения
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
MY162564A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
PH12019500853A1 (en) Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
EA200971053A1 (ru) Способы лечения кожных язв
EA201290395A1 (ru) Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций
EA201001691A1 (ru) Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
EA201300062A1 (ru) Фармацевтическая композиция, предназначенная для лечения заболеваний центральной и периферической нервной системы сосудистого, травматического, токсического, гипоксического и аутоиммунного генеза
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
EA202191735A1 (ru) Варианты альфа-галактозидазы человека
DE602004017148D1 (de) S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
EP4219521A3 (en) Cellular growth promoting peptides derived from rice proteins (oryza sativa) and uses thereof
BR112013022557A2 (pt) ligantes de peptídeo composições de polipeptídeo e métodos para uso dos mesmos
UA108779C2 (uk) Композиція та спосіб лікування раку

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU